TABLE 1.
Demographic characteristics, oncological stage and observed survival of patients stratified according to the histopathological diagnosis according to the 2013-SPRING survival prediction model
| Fast-growing metastases | Moderate-growing metastases | Slow-growing metastases | Sarcomas | Non-oncological patients | |
|---|---|---|---|---|---|
| No. of subjects | 12 | 11 | 9 | 73 | 39 |
| Mean age [years] | 63 ± 14 | 65 ± 10 | 64 ± 12 | 42 ± 21 | 53 ± 19 |
| Gender [Female/Male] | 6 / 6 | 2 / 9 | 8 / 1 | 39 / 34 | 20 / 19 |
| Percentage of patients with pathological fracture or > 1 metastasis | 75% | 73% | 44% | 18% | 0% |
| Patients alive 2 years after the operation † | 25% | 55% | 88% | 80% | 100% |
| Patients alive 5 years after the operation ‡ | 10% | 30% | 83% | 69% | 97% |
| Implant removed within 2 years after the operation † | 0% | 9% | 13% | 9% | 11% |
| Implant removed within 5 years after the operation ‡ | 10% | 10% | 17% | 18% | 19% |
FIGURE 1.
The Kaplan-Meier estimated mean survival time after surgical resection.
TABLE 2.
Cox regression analysis of patient survival for the cohort of 144 patients with tumor endoprosthetic reconstructions, stratified into histopathological groups according to the 2013-SPRING survival prediction model
| B | SE | Exp(B) | 95 % CI for Exp(B) | p-value | ||
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Age [per year] | 0.021 | 0.010 | 1.021 | 1.002 | 1.041 | 0.031* |
| Gender [male = 1] | -0.410 | 0.304 | 0.664 | 0.366 | 1.205 | 0.178 |
| Slow-growing-mets (reference) | 0.002* | |||||
| Fast-growing mets | 1.709 | 0.674 | 5.522 | 1.473 | 20.703 | 0.011* |
| Moderate-growing mets | 0.853 | 0.703 | 2.347 | 0.592 | 9.308 | 0.225 |
| Sarcomas | 0.831 | 0.661 | 2.296 | 0.629 | 8.378 | 0.208 |
| Non-oncological patients | -1.315 | 0.964 | 0.269 | 0.041 | 1.776 | 0.173 |
| Pathological fx or > 1 mets | 1.032 | 0.350 | 2.809 | 1.414 | 5.587 | 0.003* |
TABLE 3.
Cox regression analysis of patient survival for the subcohort of 32 patients with metastases, stratified into histopathological groups according to the 2013-SPRING survival prediction model
| B | SE | Exp(B) | 95 % CI for Exp(B) | p-value | ||
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Age [per year] | 0.039 | 0.037 | 1.040 | 0.967 | 1.119 | 0.293 |
| Gender [male = 1] | 0.235 | 0.622 | 1.265 | 0.373 | 4.285 | 0.706 |
| Slow-growing-mets (reference) | 0.022* | |||||
| Fast-growing mets | 1.859 | 0.898 | 6.419 | 1.105 | 37.294 | 0.038* |
| Moderate-growing mets | 0.436 | 1.014 | 1.547 | 0.212 | 11.289 | 0.667 |
| Pathological fx or > 1 mets | -0.683 | 0.725 | 0.505 | 0.122 | 2.093 | 0.346 |
| C-reactive protein [mg/L] | 0.018 | 0.008 | 1.018 | 1.003 | 1.034 | 0.021* |
| Leukocyte count [109/L] | 0.096 | 0.081 | 1.100 | 0.940 | 1.289 | 0.234 |
| Hemoglobin [g/L] | 0.027 | 0.029 | 1.027 | 0.971 | 1.087 | 0.348 |
| Thrombocyte count [109/L] | 0.000 | 0.005 | 1.000 | 0.989 | 1.011 | 0.980 |